Arterial calcification of infancy
MONDO:0018870Idiopathic arterial calcification of infancy is a rare condition characterized by extensive calcification and stenosis of the large and medium sized arteries.
Also known as: Generalized Arterial Calcification of Infancy, generalised arterial calcification of infancy, generalized arterial calcification of infancy, idiopathic infantile arterial calcification, idiopathic obliterative arteriopathy, infantile arteriosclerosis, occlusive infantile arteriopathy, IIAC
7 clinical trials for this condition and its sub-types, 7 tagged with Arterial calcification of infancy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Arterial calcification of infancy
-
Can a replacement enzyme keep calcium buildup in check?
Disease control OngoingThis trial tests the long-term safety of a drug called INZ-701 in people with rare genetic conditions that cause abnormal calcium buildup in the body. The study enrolls people who have already received INZ-701 in an earlier trial and want to continue treatment. Researchers will m…
Phase 2 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for babies: drug targets rare genetic disorder that hardens arteries
Disease control OngoingThis study tests a new medicine called INZ-701 in babies up to 1 year old who have a rare genetic condition (ENPP1 deficiency) that causes severe hardening of the arteries and bone problems. The goal is to see if the drug can raise a key substance in the blood, improve survival, …
Phase 3 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for babies with rare calcification disease: first drug trial launches
Disease control OngoingThis study tests a new drug called INZ-701 in up to 16 infants (up to 1 year old) with rare genetic conditions (ENPP1 or ABCC6 deficiency) that cause dangerous calcium buildup in arteries and other problems. The main goal is to check the drug's safety and how the body handles it,…
Phase 1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New registry aims to unlock secrets of rare genetic diseases
Knowledge-focused OngoingThis observational registry is collecting information from up to 1,000 people with ENPP1 deficiency or infantile-onset ABCC6 deficiency. The goal is to understand how these rare diseases progress over time by tracking genetic, physical, and quality-of-life changes during routine …
Sponsor: Inozyme Pharma • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC